Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
The ML18174 study, which showed benefits of bevacizumab (BEV) continuation beyond progression (BBP) for metastatic colorectal cancer (mCRC), excluded patients with first-line progression-free survival (PFS) shorter than 3 months. The present study was conducted to evaluate the efficacy of second-lin...
Saved in:
| Published in | BMC cancer Vol. 21; no. 1; pp. 1159 - 9 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
29.10.2021
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The ML18174 study, which showed benefits of bevacizumab (BEV) continuation beyond progression (BBP) for metastatic colorectal cancer (mCRC), excluded patients with first-line progression-free survival (PFS) shorter than 3 months. The present study was conducted to evaluate the efficacy of second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab.
The subjects of this study were mCRC patients who experienced disease progression < 100 days from commencement of first-line chemotherapy containing BEV initiated between Apr 2007 and Dec 2016. Second-line chemotherapy regimens were classified into two groups with and without BEV/other anti-angiogenic agents (BBP and non-BBP) and efficacy and safety were compared using univariate and multivariate analysis.
Sixty-one patients were identified as subjects of this study. Baseline characteristics were numerically different between BBP (n = 37) and non-BBP (n = 25) groups, such as performance status (0-1/> 2/unknown: 89/8/3 and 56/40/4%), RAS status (wild/mutant/unknown: 32/54/16 and 76/16/8%). Response rate was 8.6% in BBP group and 9.1% in non-BBP group (p = 1.00). Median PFS was 3.9 months in BBP group and 2.8 months in non-BBP group (HR [95%CI]: 0.79 [0.46-1.34], p = 0.373, adjusted HR: 0.87 [0.41-1.82], p = 0.707). Median overall survival was 8.5 months in BBP group and 5.4 months in non-BBP group (HR 0.66 [0.38-1.12], p = 0.125, adjusted HR 0.53 [0.27-1.07], p = 0.078).
In mCRC patients who experienced early progression in first-line chemotherapy, second-line chemotherapy showed poor clinical outcomes regardless use of anti-angiogenic agents. |
|---|---|
| AbstractList | Background The ML18174 study, which showed benefits of bevacizumab (BEV) continuation beyond progression (BBP) for metastatic colorectal cancer (mCRC), excluded patients with first-line progression-free survival (PFS) shorter than 3 months. The present study was conducted to evaluate the efficacy of second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab. Methods The subjects of this study were mCRC patients who experienced disease progression < 100 days from commencement of first-line chemotherapy containing BEV initiated between Apr 2007 and Dec 2016. Second-line chemotherapy regimens were classified into two groups with and without BEV/other anti-angiogenic agents (BBP and non-BBP) and efficacy and safety were compared using univariate and multivariate analysis. Results Sixty-one patients were identified as subjects of this study. Baseline characteristics were numerically different between BBP (n = 37) and non-BBP (n = 25) groups, such as performance status (0–1/> 2/unknown: 89/8/3 and 56/40/4%), RAS status (wild/mutant/unknown: 32/54/16 and 76/16/8%). Response rate was 8.6% in BBP group and 9.1% in non-BBP group (p = 1.00). Median PFS was 3.9 months in BBP group and 2.8 months in non-BBP group (HR [95%CI]: 0.79 [0.46–1.34], p = 0.373, adjusted HR: 0.87 [0.41–1.82], p = 0.707). Median overall survival was 8.5 months in BBP group and 5.4 months in non-BBP group (HR 0.66 [0.38–1.12], p = 0.125, adjusted HR 0.53 [0.27–1.07], p = 0.078). Conclusion In mCRC patients who experienced early progression in first-line chemotherapy, second-line chemotherapy showed poor clinical outcomes regardless use of anti-angiogenic agents. Background The ML18174 study, which showed benefits of bevacizumab (BEV) continuation beyond progression (BBP) for metastatic colorectal cancer (mCRC), excluded patients with first-line progression-free survival (PFS) shorter than 3 months. The present study was conducted to evaluate the efficacy of second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab. Methods The subjects of this study were mCRC patients who experienced disease progression < 100 days from commencement of first-line chemotherapy containing BEV initiated between Apr 2007 and Dec 2016. Second-line chemotherapy regimens were classified into two groups with and without BEV/other anti-angiogenic agents (BBP and non-BBP) and efficacy and safety were compared using univariate and multivariate analysis. Results Sixty-one patients were identified as subjects of this study. Baseline characteristics were numerically different between BBP (n = 37) and non-BBP (n = 25) groups, such as performance status (0-1/ 2/unknown: 89/8/3 and 56/40/4%), RAS status (wild/mutant/unknown: 32/54/16 and 76/16/8%). Response rate was 8.6% in BBP group and 9.1% in non-BBP group (p = 1.00). Median PFS was 3.9 months in BBP group and 2.8 months in non-BBP group (HR [95%CI]: 0.79 [0.46-1.34], p = 0.373, adjusted HR: 0.87 [0.41-1.82], p = 0.707). Median overall survival was 8.5 months in BBP group and 5.4 months in non-BBP group (HR 0.66 [0.38-1.12], p = 0.125, adjusted HR 0.53 [0.27-1.07], p = 0.078). Conclusion In mCRC patients who experienced early progression in first-line chemotherapy, second-line chemotherapy showed poor clinical outcomes regardless use of anti-angiogenic agents. Keywords: Metastatic colorectal cancer, Bevacizumab continuation beyond progression, Early disease progression, Second-line chemotherapy The ML18174 study, which showed benefits of bevacizumab (BEV) continuation beyond progression (BBP) for metastatic colorectal cancer (mCRC), excluded patients with first-line progression-free survival (PFS) shorter than 3 months. The present study was conducted to evaluate the efficacy of second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab. The subjects of this study were mCRC patients who experienced disease progression < 100 days from commencement of first-line chemotherapy containing BEV initiated between Apr 2007 and Dec 2016. Second-line chemotherapy regimens were classified into two groups with and without BEV/other anti-angiogenic agents (BBP and non-BBP) and efficacy and safety were compared using univariate and multivariate analysis. Sixty-one patients were identified as subjects of this study. Baseline characteristics were numerically different between BBP (n = 37) and non-BBP (n = 25) groups, such as performance status (0-1/ 2/unknown: 89/8/3 and 56/40/4%), RAS status (wild/mutant/unknown: 32/54/16 and 76/16/8%). Response rate was 8.6% in BBP group and 9.1% in non-BBP group (p = 1.00). Median PFS was 3.9 months in BBP group and 2.8 months in non-BBP group (HR [95%CI]: 0.79 [0.46-1.34], p = 0.373, adjusted HR: 0.87 [0.41-1.82], p = 0.707). Median overall survival was 8.5 months in BBP group and 5.4 months in non-BBP group (HR 0.66 [0.38-1.12], p = 0.125, adjusted HR 0.53 [0.27-1.07], p = 0.078). In mCRC patients who experienced early progression in first-line chemotherapy, second-line chemotherapy showed poor clinical outcomes regardless use of anti-angiogenic agents. The ML18174 study, which showed benefits of bevacizumab (BEV) continuation beyond progression (BBP) for metastatic colorectal cancer (mCRC), excluded patients with first-line progression-free survival (PFS) shorter than 3 months. The present study was conducted to evaluate the efficacy of second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab. The subjects of this study were mCRC patients who experienced disease progression < 100 days from commencement of first-line chemotherapy containing BEV initiated between Apr 2007 and Dec 2016. Second-line chemotherapy regimens were classified into two groups with and without BEV/other anti-angiogenic agents (BBP and non-BBP) and efficacy and safety were compared using univariate and multivariate analysis. Sixty-one patients were identified as subjects of this study. Baseline characteristics were numerically different between BBP (n = 37) and non-BBP (n = 25) groups, such as performance status (0-1/> 2/unknown: 89/8/3 and 56/40/4%), RAS status (wild/mutant/unknown: 32/54/16 and 76/16/8%). Response rate was 8.6% in BBP group and 9.1% in non-BBP group (p = 1.00). Median PFS was 3.9 months in BBP group and 2.8 months in non-BBP group (HR [95%CI]: 0.79 [0.46-1.34], p = 0.373, adjusted HR: 0.87 [0.41-1.82], p = 0.707). Median overall survival was 8.5 months in BBP group and 5.4 months in non-BBP group (HR 0.66 [0.38-1.12], p = 0.125, adjusted HR 0.53 [0.27-1.07], p = 0.078). In mCRC patients who experienced early progression in first-line chemotherapy, second-line chemotherapy showed poor clinical outcomes regardless use of anti-angiogenic agents. The ML18174 study, which showed benefits of bevacizumab (BEV) continuation beyond progression (BBP) for metastatic colorectal cancer (mCRC), excluded patients with first-line progression-free survival (PFS) shorter than 3 months. The present study was conducted to evaluate the efficacy of second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab.BACKGROUNDThe ML18174 study, which showed benefits of bevacizumab (BEV) continuation beyond progression (BBP) for metastatic colorectal cancer (mCRC), excluded patients with first-line progression-free survival (PFS) shorter than 3 months. The present study was conducted to evaluate the efficacy of second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab.The subjects of this study were mCRC patients who experienced disease progression < 100 days from commencement of first-line chemotherapy containing BEV initiated between Apr 2007 and Dec 2016. Second-line chemotherapy regimens were classified into two groups with and without BEV/other anti-angiogenic agents (BBP and non-BBP) and efficacy and safety were compared using univariate and multivariate analysis.METHODSThe subjects of this study were mCRC patients who experienced disease progression < 100 days from commencement of first-line chemotherapy containing BEV initiated between Apr 2007 and Dec 2016. Second-line chemotherapy regimens were classified into two groups with and without BEV/other anti-angiogenic agents (BBP and non-BBP) and efficacy and safety were compared using univariate and multivariate analysis.Sixty-one patients were identified as subjects of this study. Baseline characteristics were numerically different between BBP (n = 37) and non-BBP (n = 25) groups, such as performance status (0-1/> 2/unknown: 89/8/3 and 56/40/4%), RAS status (wild/mutant/unknown: 32/54/16 and 76/16/8%). Response rate was 8.6% in BBP group and 9.1% in non-BBP group (p = 1.00). Median PFS was 3.9 months in BBP group and 2.8 months in non-BBP group (HR [95%CI]: 0.79 [0.46-1.34], p = 0.373, adjusted HR: 0.87 [0.41-1.82], p = 0.707). Median overall survival was 8.5 months in BBP group and 5.4 months in non-BBP group (HR 0.66 [0.38-1.12], p = 0.125, adjusted HR 0.53 [0.27-1.07], p = 0.078).RESULTSSixty-one patients were identified as subjects of this study. Baseline characteristics were numerically different between BBP (n = 37) and non-BBP (n = 25) groups, such as performance status (0-1/> 2/unknown: 89/8/3 and 56/40/4%), RAS status (wild/mutant/unknown: 32/54/16 and 76/16/8%). Response rate was 8.6% in BBP group and 9.1% in non-BBP group (p = 1.00). Median PFS was 3.9 months in BBP group and 2.8 months in non-BBP group (HR [95%CI]: 0.79 [0.46-1.34], p = 0.373, adjusted HR: 0.87 [0.41-1.82], p = 0.707). Median overall survival was 8.5 months in BBP group and 5.4 months in non-BBP group (HR 0.66 [0.38-1.12], p = 0.125, adjusted HR 0.53 [0.27-1.07], p = 0.078).In mCRC patients who experienced early progression in first-line chemotherapy, second-line chemotherapy showed poor clinical outcomes regardless use of anti-angiogenic agents.CONCLUSIONIn mCRC patients who experienced early progression in first-line chemotherapy, second-line chemotherapy showed poor clinical outcomes regardless use of anti-angiogenic agents. Abstract Background The ML18174 study, which showed benefits of bevacizumab (BEV) continuation beyond progression (BBP) for metastatic colorectal cancer (mCRC), excluded patients with first-line progression-free survival (PFS) shorter than 3 months. The present study was conducted to evaluate the efficacy of second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab. Methods The subjects of this study were mCRC patients who experienced disease progression < 100 days from commencement of first-line chemotherapy containing BEV initiated between Apr 2007 and Dec 2016. Second-line chemotherapy regimens were classified into two groups with and without BEV/other anti-angiogenic agents (BBP and non-BBP) and efficacy and safety were compared using univariate and multivariate analysis. Results Sixty-one patients were identified as subjects of this study. Baseline characteristics were numerically different between BBP (n = 37) and non-BBP (n = 25) groups, such as performance status (0–1/> 2/unknown: 89/8/3 and 56/40/4%), RAS status (wild/mutant/unknown: 32/54/16 and 76/16/8%). Response rate was 8.6% in BBP group and 9.1% in non-BBP group (p = 1.00). Median PFS was 3.9 months in BBP group and 2.8 months in non-BBP group (HR [95%CI]: 0.79 [0.46–1.34], p = 0.373, adjusted HR: 0.87 [0.41–1.82], p = 0.707). Median overall survival was 8.5 months in BBP group and 5.4 months in non-BBP group (HR 0.66 [0.38–1.12], p = 0.125, adjusted HR 0.53 [0.27–1.07], p = 0.078). Conclusion In mCRC patients who experienced early progression in first-line chemotherapy, second-line chemotherapy showed poor clinical outcomes regardless use of anti-angiogenic agents. |
| ArticleNumber | 1159 |
| Audience | Academic |
| Author | Yamamoto, Shun Masuishi, Toshiki Kawakami, Kentaro Moriwaki, Toshikazu Okuda, Hiroyuki Tsuji, Yasushi Nakajima, Takako Eguchi Izawa, Naoki Yamamoto, Yoshiyuki Makiyama, Akitaka Boku, Narikazu Yamazaki, Kentaro Esaki, Taito Nagashima, Kengo Komoda, Masato Kawakami, Takeshi Mitani, Seiichiro |
| Author_xml | – sequence: 1 givenname: Shun surname: Yamamoto fullname: Yamamoto, Shun – sequence: 2 givenname: Kengo surname: Nagashima fullname: Nagashima, Kengo – sequence: 3 givenname: Takeshi surname: Kawakami fullname: Kawakami, Takeshi – sequence: 4 givenname: Seiichiro surname: Mitani fullname: Mitani, Seiichiro – sequence: 5 givenname: Masato surname: Komoda fullname: Komoda, Masato – sequence: 6 givenname: Yasushi surname: Tsuji fullname: Tsuji, Yasushi – sequence: 7 givenname: Naoki surname: Izawa fullname: Izawa, Naoki – sequence: 8 givenname: Kentaro surname: Kawakami fullname: Kawakami, Kentaro – sequence: 9 givenname: Yoshiyuki surname: Yamamoto fullname: Yamamoto, Yoshiyuki – sequence: 10 givenname: Akitaka surname: Makiyama fullname: Makiyama, Akitaka – sequence: 11 givenname: Kentaro surname: Yamazaki fullname: Yamazaki, Kentaro – sequence: 12 givenname: Toshiki surname: Masuishi fullname: Masuishi, Toshiki – sequence: 13 givenname: Taito surname: Esaki fullname: Esaki, Taito – sequence: 14 givenname: Takako Eguchi surname: Nakajima fullname: Nakajima, Takako Eguchi – sequence: 15 givenname: Hiroyuki surname: Okuda fullname: Okuda, Hiroyuki – sequence: 16 givenname: Toshikazu surname: Moriwaki fullname: Moriwaki, Toshikazu – sequence: 17 givenname: Narikazu orcidid: 0000-0002-1438-707X surname: Boku fullname: Boku, Narikazu |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34715820$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9k8tu1DAUhiNURC_wAixQJCQEixTbSRxng1RVXEaqhERhbZ04xzOuEnuwncLwLrwrTqeFmapCXtg6_v4_8bkcZwfWWcyy55ScUir420CZEHVBGC2IEC0p-KPsiFYNLVhFmoOd82F2HMIVIbQRRDzJDst0UQtGjrLfl6ic7YvBWMzVCkcXV-hhvclBR_Q5gh82eW8CQsB87d3SYwjG2byfvLHLXBsf4gPy5BrB2Bnp8BqU-TWN0OXa-XwN0aCNIf9h4iofMUKIKaSSZnAeVYQhV2AV-qfZYw1DwGe3-0n27cP7r-efiovPHxfnZxeF4kzEokaqK8GAYs8VQCe6UrUMRVsrDZTWDWFVLXipeiibTnMCZc-wIRUnVLGelSfZYuvbO7iSa29G8BvpwMibgPNLCT794YBSa1UK0jVVy8tKlFoorqFqGE8HwalKXu-2XuupG7FX6aUehj3T_RtrVnLprqWo65qKMhm8vjXw7vuEIcrRBIXDABbdFCSrW5LqnSqZ0Jf30Cs3eZtSNVMtrWpWs3_UEtIDjNUufVfNpvKMC8orztrZ6_QBKq0eR5Oqidqk-J7gzZ5grjj-jEuYQpCLyy_77KsddoUwxFVwwxRTJ4V98MVu9v6m7a5jEyC2gPIuBI9aKjN3j5uTaQZJiZyHQ26HQ6bhkDfDIXmSsnvSO_f_iP4A0GgS1w |
| CitedBy_id | crossref_primary_10_1016_j_esmoop_2022_100748 crossref_primary_10_3390_cancers14030802 crossref_primary_10_1007_s40278_022_18223_9 crossref_primary_10_3390_medicina58050607 |
| Cites_doi | 10.1200/JCO.2012.42.2592 10.1002/1097-0142(20000801)89:3<488::AID-CNCR3>3.0.CO;2-X 10.1093/annonc/mdq632 10.1093/annonc/mdw235 10.18632/oncotarget.1671 10.1093/annonc/mdw206 10.1093/annonc/mdw402 10.1002/bies.950130106 10.1158/1078-0432.CCR-19-1985 10.18632/oncotarget.7008 10.1200/JCO.2008.16.3212 10.1200/JCO.2017.35.15_suppl.3503 10.1093/annonc/mdx816 10.1371/journal.pone.0077117 10.1093/annonc/mdf034 10.1200/JCO.2016.34.15_suppl.3504 10.1038/nrc3183 10.1111/cas.13098 10.1016/S1470-2045(12)70477-1 10.1158/1078-0432.CCR-12-1913 10.1093/annonc/mdx767 10.1007/s11523-015-0402-9 10.1200/JCO.2009.27.6055 10.1200/JCO.2016.34.15_suppl.3597 10.1093/annonc/mdx175 10.1158/1078-0432.CCR-05-1682 10.1093/annonc/mdx738 10.1002/pds.3633 10.1001/jama.2010.1535 10.1200/JCO.2007.13.1193 10.1177/1756283X13502637 10.1016/S1470-2045(10)70130-3 |
| ContentType | Journal Article |
| Copyright | 2021. The Author(s). COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2021 |
| Copyright_xml | – notice: 2021. The Author(s). – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2021 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12885-021-08890-6 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Open Access Full Text url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 9 |
| ExternalDocumentID | oai_doaj_org_article_ffc380b74963483f8c6fa47268c6861c PMC8555183 A681646298 34715820 10_1186_s12885_021_08890_6 |
| Genre | Multicenter Study Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c628t-5e1f482a1ed6caab8b3c92e895cfa11570245863cda37bf60a3d2e704601c2d23 |
| IEDL.DBID | M48 |
| ISSN | 1471-2407 |
| IngestDate | Wed Aug 27 01:30:49 EDT 2025 Sun Aug 31 08:12:03 EDT 2025 Fri Jul 11 15:48:25 EDT 2025 Fri Jul 25 07:51:26 EDT 2025 Tue Jun 17 21:31:37 EDT 2025 Tue Jun 10 20:37:12 EDT 2025 Fri Jun 27 05:10:29 EDT 2025 Thu May 22 21:21:20 EDT 2025 Mon Jul 21 05:25:47 EDT 2025 Tue Jul 01 04:29:10 EDT 2025 Thu Apr 24 23:07:03 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Second-line chemotherapy Early disease progression Metastatic colorectal cancer Bevacizumab continuation beyond progression |
| Language | English |
| License | 2021. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c628t-5e1f482a1ed6caab8b3c92e895cfa11570245863cda37bf60a3d2e704601c2d23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-1438-707X |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12885-021-08890-6 |
| PMID | 34715820 |
| PQID | 2599145252 |
| PQPubID | 44074 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_ffc380b74963483f8c6fa47268c6861c pubmedcentral_primary_oai_pubmedcentral_nih_gov_8555183 proquest_miscellaneous_2590088808 proquest_journals_2599145252 gale_infotracmisc_A681646298 gale_infotracacademiconefile_A681646298 gale_incontextgauss_ISR_A681646298 gale_healthsolutions_A681646298 pubmed_primary_34715820 crossref_citationtrail_10_1186_s12885_021_08890_6 crossref_primary_10_1186_s12885_021_08890_6 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-10-29 |
| PublicationDateYYYYMMDD | 2021-10-29 |
| PublicationDate_xml | – month: 10 year: 2021 text: 2021-10-29 day: 29 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC cancer |
| PublicationTitleAlternate | BMC Cancer |
| PublicationYear | 2021 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | J Tabernero (8890_CR26) 2018; 29 PA Tang (8890_CR23) 2013; 6 JR Tonra (8890_CR25) 2006; 12 E Van Custem (8890_CR1) 2016; 27 8890_CR2 RS Kerbel (8890_CR7) 1991; 13 E Van Custem (8890_CR28) 2016; 11 M Peeters (8890_CR34) 2013; 19 V Derangère (8890_CR29) 2016; 9 W De Roock (8890_CR9) 2010; 304 CH Köhne (8890_CR8) 2002; 13 B Keith (8890_CR31) 2011; 12 E Van Custem (8890_CR32) 2012; 29 8890_CR20 8890_CR21 R Obermannova (8890_CR27) 2016; 27 Y Yamada (8890_CR19) 2018; 29 CH Lieu (8890_CR22) 2013; 8 S Tejpar (8890_CR10) 2012; 30 K Shitara (8890_CR17) 2016; 107 M Peeters (8890_CR16) 2010; 28 W De Roock (8890_CR11) 2010; 11 AF Sobrero (8890_CR15) 2008; 26 A Grothey (8890_CR5) 2014; 23 CJ Bruns (8890_CR24) 2000; 89 C Bokemeyer (8890_CR33) 2011; 22 T Yoshino (8890_CR3) 2018; 29 J Bennoua (8890_CR6) 2013; 14 A Grothey (8890_CR4) 2008; 26 P Mésange (8890_CR30) 2014; 5 K Yamazaki (8890_CR18) 2016; 27 8890_CR12 8890_CR13 D Arnold (8890_CR14) 2017; 28 |
| References_xml | – volume: 30 start-page: 3570 issue: 29 year: 2012 ident: 8890_CR10 publication-title: J Clin Oncol doi: 10.1200/JCO.2012.42.2592 – volume: 89 start-page: 488 issue: 3 year: 2000 ident: 8890_CR24 publication-title: Cancer doi: 10.1002/1097-0142(20000801)89:3<488::AID-CNCR3>3.0.CO;2-X – volume: 22 start-page: 1535 issue: 7 year: 2011 ident: 8890_CR33 publication-title: Ann Oncol doi: 10.1093/annonc/mdq632 – volume: 27 start-page: 1386 issue: 8 year: 2016 ident: 8890_CR1 publication-title: Ann Oncol doi: 10.1093/annonc/mdw235 – volume: 5 start-page: 4709 issue: 13 year: 2014 ident: 8890_CR30 publication-title: Oncotarget. doi: 10.18632/oncotarget.1671 – volume: 27 start-page: 1539 issue: 8 year: 2016 ident: 8890_CR18 publication-title: Ann Oncol doi: 10.1093/annonc/mdw206 – volume: 27 start-page: 2082 issue: 11 year: 2016 ident: 8890_CR27 publication-title: Ann Oncol doi: 10.1093/annonc/mdw402 – volume: 13 start-page: 31 issue: 1 year: 1991 ident: 8890_CR7 publication-title: Bioessays doi: 10.1002/bies.950130106 – ident: 8890_CR21 doi: 10.1158/1078-0432.CCR-19-1985 – volume: 9 start-page: 9309 issue: 8 year: 2016 ident: 8890_CR29 publication-title: Oncotarget. doi: 10.18632/oncotarget.7008 – volume: 26 start-page: 5326 issue: 33 year: 2008 ident: 8890_CR4 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.16.3212 – ident: 8890_CR13 doi: 10.1200/JCO.2017.35.15_suppl.3503 – volume: 29 start-page: 624 issue: 3 year: 2018 ident: 8890_CR19 publication-title: Ann Oncol doi: 10.1093/annonc/mdx816 – volume: 8 start-page: e77117 issue: 10 year: 2013 ident: 8890_CR22 publication-title: PLoS One doi: 10.1371/journal.pone.0077117 – volume: 13 start-page: 308 issue: 2 year: 2002 ident: 8890_CR8 publication-title: Ann Oncol doi: 10.1093/annonc/mdf034 – ident: 8890_CR12 doi: 10.1200/JCO.2016.34.15_suppl.3504 – volume: 12 start-page: 9 issue: 1 year: 2011 ident: 8890_CR31 publication-title: Nat Rev Cancer doi: 10.1038/nrc3183 – volume: 107 start-page: 1843 issue: 12 year: 2016 ident: 8890_CR17 publication-title: Cancer Sci doi: 10.1111/cas.13098 – volume: 14 start-page: 29 issue: 1 year: 2013 ident: 8890_CR6 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70477-1 – volume: 19 start-page: 1902 issue: 7 year: 2013 ident: 8890_CR34 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-1913 – volume: 29 start-page: 602 issue: 3 year: 2018 ident: 8890_CR26 publication-title: Ann Oncol doi: 10.1093/annonc/mdx767 – volume: 11 start-page: 383 issue: 3 year: 2016 ident: 8890_CR28 publication-title: Target Oncol doi: 10.1007/s11523-015-0402-9 – ident: 8890_CR2 – volume: 29 start-page: 2011 year: 2012 ident: 8890_CR32 publication-title: J Clin Oncol – volume: 28 start-page: 4706 issue: 31 year: 2010 ident: 8890_CR16 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.27.6055 – ident: 8890_CR20 doi: 10.1200/JCO.2016.34.15_suppl.3597 – volume: 28 start-page: 1713 issue: 8 year: 2017 ident: 8890_CR14 publication-title: Ann Oncol doi: 10.1093/annonc/mdx175 – volume: 12 start-page: 2197 issue: 7 year: 2006 ident: 8890_CR25 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-05-1682 – volume: 29 start-page: 44 issue: 1 year: 2018 ident: 8890_CR3 publication-title: Ann Oncol doi: 10.1093/annonc/mdx738 – volume: 23 start-page: 726 issue: 7 year: 2014 ident: 8890_CR5 publication-title: Pharmarcoepidemiol Drug Saf doi: 10.1002/pds.3633 – volume: 304 start-page: 1812 issue: 16 year: 2010 ident: 8890_CR9 publication-title: JAMA doi: 10.1001/jama.2010.1535 – volume: 26 start-page: 2311 issue: 14 year: 2008 ident: 8890_CR15 publication-title: J Clin Oncol doi: 10.1200/JCO.2007.13.1193 – volume: 6 start-page: 459 issue: 6 year: 2013 ident: 8890_CR23 publication-title: Ther Adv Gastroenterol doi: 10.1177/1756283X13502637 – volume: 11 start-page: 753 issue: 8 year: 2010 ident: 8890_CR11 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70130-3 |
| SSID | ssj0017808 |
| Score | 2.3503556 |
| Snippet | The ML18174 study, which showed benefits of bevacizumab (BEV) continuation beyond progression (BBP) for metastatic colorectal cancer (mCRC), excluded patients... Background The ML18174 study, which showed benefits of bevacizumab (BEV) continuation beyond progression (BBP) for metastatic colorectal cancer (mCRC),... Abstract Background The ML18174 study, which showed benefits of bevacizumab (BEV) continuation beyond progression (BBP) for metastatic colorectal cancer... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1159 |
| SubjectTerms | Adult Aged Aged, 80 and over Analysis of Variance Angiogenesis Angiogenesis Inhibitors - therapeutic use Antiangiogenic agents Antibodies Antineoplastic Agents, Immunological - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Bevacizumab - therapeutic use Bevacizumab continuation beyond progression Camptothecin - analogs & derivatives Camptothecin - therapeutic use Cancer Chemotherapy Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Confidence intervals Cytotoxicity Disease control Disease Progression Drug Administration Schedule Drug therapy Early disease progression Female Fluorouracil - therapeutic use Humans Irinotecan - therapeutic use Japan Leucovorin - therapeutic use Male Medical prognosis Metastases Metastasis Metastatic colorectal cancer Middle Aged Monoclonal antibodies Multivariate analysis Neutropenia Organoplatinum Compounds - therapeutic use Oxaliplatin - therapeutic use Patient outcomes Patients Progression-Free Survival Pyrimidines - therapeutic use Retrospective Studies Second-line chemotherapy Survival Targeted cancer therapy Time Factors |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yD-KLeH5WT40i-CDltkmbTh9P8TiF88Hz4N5CPnXB7cp190D_F_9XZ9LsskXRFx8WymZS2sxk8ktn5hfGXkQE4bWRqox140v8NaW1ti2jVR6iNJVJuTmnH9TJef3-ornYOeqLcsJGeuBx4A5jdBJmtq3RUmqQEZyKpm6FwgtQlSPvi2veZjOV4wctzGBTIgPqcEAvDFSJTJ8DocMN02QZSmz9v_vknUVpmjC5swId32I3M3TkR-Mj77Nrob_Nrp_m4Pgd9vOMNre-JODIUReLXFz1naeDwHkgLmOeIzI8JWaNpBx8rFXkcY5Q8A_dKZ19PEiC23Bl3PzHemEsR7jLMy3rwOl7Ll-ElaEKpbnjRIZNzhQf2JFhXd5l58dvP705KfPpC6VTAlZlE6pYgzBV8MoZY8FK14kAXeOiIYoeCtqCks4b2dqoZkZ6EVoKtFZOeCHvsb1-2YcHjPvOBFdHqIysEUBA57vKNpZCqLX1xhSs2ihDu0xNTidkfNVpiwJKjwrUqECdFKhVwV5t-3wbiTn-Kv2adLyVJFLt9Aeams6mpv9lagV7ShaixwrVrWvQRwqIpU10ULDnSYKINXrK3Pls1sOg3519nAi9zEJxiW_pTC6EwLEiLq6J5MFEEme-mzZvTFVnzzNo3M52FQWrRcGebZupJ2XT9WG5TjII_dBz4y3uj5a9HRmJaKVBWFiwdmLzk6GbtvTzL4mXHBqi95MP_8dYP2I3BE1XRAmiO2B7q8t1eIzwb2WfpJn-C3pXWeY priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection (Proquest) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgiftvz1CiCD1Jum7Rp-iSneJzC-eB5sG8hn-eC295tdwX9X_xfnUmz9YpyDwvLZrK0mWTyS2bmN4S8CgDCS81FHsrK5fCpcmNMnQcjnAxcFzrG5hx_Fken5ad5NU8Xbn0Kq9zaxGioXWfxjnwfYHpToBOOvT2_yLFqFHpXUwmN6-QGUpdhSFc9Hw9cRS1ncpsoI8V-D7ZYYj4yXgrKBo5Nk80ocvb_a5kvbU3TsMlL-9DhHXI7AUh6MGj8Lrnm23vk5nFykd8nv0_wiOtyhI8UNLJMKVY_aSwHTj0yGtPkl6ExPGug5qBDxiINCwCE_-mOQe1DOQlq_A9tF782S20ogF6ayFl7ire6dOnXGvOUFpYiJTaaVHhgi9Nr9YCcHn74-v4oTzUYciuYXOeVL0IpmS68E1ZrIw23DfOyqWzQSNSDrlspuHWa1yaImeaO-RrdrYVljvGHZKftWv-YUNdob8sgC81LgBGycU1hKoOO1NI4rTNSbJWhbCIoxzoZ31U8qEihBgUqUKCKClQiI2_GPucDPceV0u9Qx6MkUmvHH7rVmUorVYVguZyZugTTVEoepBVBlzUT8EWKwmbkOc4QNeSpjgZCHQiJXG2skRl5GSWQXqPF-J0zvel79fHky0TodRIKHbyl1SkdAsYKGbkmknsTSVj_dtq8naoq2Z9e_V0tGXkxNmNPjKlrfbeJMgAAwX7DXzwaZvY4MhwwSwXgMCP1ZM5Phm7a0i6-RXZyWSHJH9-9-rGekFsMFyKgANbskZ31auOfArxbm2dxDf8Bf1FR4Q priority: 102 providerName: ProQuest |
| Title | Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34715820 https://www.proquest.com/docview/2599145252 https://www.proquest.com/docview/2590088808 https://pubmed.ncbi.nlm.nih.gov/PMC8555183 https://doaj.org/article/ffc380b74963483f8c6fa47268c6861c |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dixMxEA_3AeKL-O3qWaMIPsjqbbKbzT6IXOWOU-ghPQuHLyHJJmfhutV-iOf_4v_qTDatt1gEH1pKM1nazEcmmZnfEPLcgxOeay5Snxd1Cq8iNcaUqTeilp7rTIfcnMGJOB7lH86Ksy2yancUF3C-8WiH_aRGs4tXP75dvgWFfxMUXorXc7CxEuuM8bJPVnAc2ia7sDOVqKiD_E9UoZShQ10GBhmjCuWqiGbjMzobVcDz_9tqX9m2uimVV_aoo5vkRnQu6UErDbfIlmtuk2uDGD6_Q36d4vG3TtG1pMCtSSy_uqShVTh1iHZMY8yGhtStFraDttWM1I_BWdwwHRPe21YT1Ljv2o5_LifaUHCIaQRunVO88aUTt9BYwzS2FOGy0dzCD7YoerO7ZHR0-OndcRr7M6RWMLlIC5f5XDKduVpYrY003FbMyaqwXiOID4Z1peC21rw0XuxrXjNXYig2s6xm_B7ZaaaNe0BoXWlncy8zzXNwMWRVV5kpDAZZc1NrnZBsxQxlI3g59tC4UOEQI4VqGaiAgSowUImEvFzP-dpCd_yTuo88XlMi7Hb4Yjo7V1GLlfeWy31T5mC2csm9tMLrvGQCPkiR2YQ8QQlRbQ3r2nioAyERx41VMiHPAgVCbzSY23Oul_O5en867BC9iER-Cv_S6lgqAWuFaF0dyr0OJdgG2x1eiapaqZaCA2-VYTibJeTpehhnYr5d46bLQAPOIdh2eMT9VrLXK8NBfQpwHBNSdmS-s3TdkWb8JSCXywIBAPnD_-LMI3KdoV6Cw8CqPbKzmC3dY_AEF6ZHtsuzskd2-4cnH4e9cJ_SCyoP78P-598TsV9E |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemTgJeEN8EBjMIxAOK1jiJ4zwgtMGmla0V2oe0N8927FGJpqMfoPG_8C_wN3KXOGERaG97qNTWlyr1Xc4_--5-R8grByA8UTEPXZIWIbzSUGudhU7zQrhYRarKzRmO-O5x8ukkPVkhv5taGEyrbHxi5aiLqcEz8g2A6XmEQTj2_vxbiF2jMLratNCozWLPXvyALdv83eAj6Pc1YzvbRx92Q99VIDSciUWY2sglgqnIFtwopYWOTc6syFPjFFLPYDBS8NgUKs60430VF8xmGECMDCuQ6ABc_moSw-ceWd3aHn0-aOMWmeiLpjRH8I05eH-BFdB4DCly2Kh1lr-qS8C_a8GlxbCbqHlp5du5Q257yEo3axu7S1ZseY_cGPqg_H3y6xA31UWIgJWCDUx8UdcFrRqQU4scytRHgmiVEFaTgdC6RpK6MUDQ_1yOafR1Awuq7Xdlxj-XE6UpwGzq6WDnFM-R6cQuFFZGjQ1FEm504nDDBg169oAcX4t-HpJeOS3tY0KLXFmTOBGpOAHgIvIij3SqMXSb6EKpgESNMqTxlOjYmeOrrLZGgstagRIUKCsFSh6Qt-015zUhyJXSW6jjVhLJvKsvprMz6X2DdM7Eoq-zBJxhImInDHcqyRiHN4JHJiDraCGyroxtXZLc5ALZ4VguAvKykkBCjxIzhs7Ucj6Xg8ODjtAbL-Sm8C-N8gUYMFfIAdaRXOtIgscx3eHGVKX3eHP59_kMyIt2GK_ELL7STpeVDEBOWDHgJx7Vlt3OTAwoKQU4GpCsY_OdqeuOlOMvFR-6SJFWMH5y9W2tk5u7R8N9uT8Y7T0ltxg-lIBBWL5GeovZ0j4DcLnQz_0TTcnpdTuRP02ukB4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Second-line+chemotherapy+after+early+disease+progression+during+first-line+chemotherapy+containing+bevacizumab+for+patients+with+metastatic+colorectal+cancer&rft.jtitle=BMC+cancer&rft.au=Yamamoto%2C+Shun&rft.au=Nagashima%2C+Kengo&rft.au=Kawakami%2C+Takeshi&rft.au=Mitani%2C+Seiichiro&rft.date=2021-10-29&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs12885-021-08890-6&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12885_021_08890_6 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |